Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

463.43 -0.57 (-0.12%)
Official Closing Price Updated: 4:15 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
 
Via Benzinga
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Alnylam Delivers a Big Q4 Earnings Beat
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress. 
Via The Motley Fool
Earnings Scheduled For February 13, 2025
 
Via Benzinga
Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views
 
Via Benzinga
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
 
Via Benzinga
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
 
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
 
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
 
Via Benzinga
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings)
 
Via Benzinga
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
 
Via Benzinga
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
 
Via Benzinga
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
 
Via Benzinga
This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.